CRVO News & Events

CervoMed presented placebo-controlled magnetic resonance imaging analyses providing evidence that neflamapimod may increase the size and enhance the function of the basal forebrain in patients with dementia with Lewy bodies, or DLB. The findings from further analysis of the RewinD-LB Phase 2b clinical trial showed that right basal forebrain volume increased by 3.5% with neflamapimod treatment and decreased by 4.2% with placebo. CervoMed plans to initiate a Phase 3 trial in the second half of 2026. "Atrophy in the basal forebrain is an important driver of clinical symptoms and progression of DLB. Combined with our previously reported data in neflamapimod treated-patients with early AD, where we saw very similar effects on the basal forebrain, these MRI analyses provide strong evidence that neflamapimod is acting on the underlying cause of DLB by reducing basal forebrain atrophy, reinforcing our clinical and biomarker data and enhancing our belief that neflamapimod has the potential to make a meaningful difference for patients with DLB," said John Alam, CEO of CervoMed.

CervoMed announced that, at the AD/PD 2026 Conference in Copenhagen, Denmark, investigators will present new analyses from the Phase 2b RewinD-LB clinical trial of neflamapimod, being developed by CervoMed, for the treatment of dementia with Lewy bodies, or DLB. The new data analyses reinforce that neflamapimod, which targets the neuroinflammation and synaptic dysfunction associated with DLB, has the potential to slow disease progression by acting on the underlying disease biology. New analyses show DLB patients with lower plasma pTau181 levels - indicating an earlier stage of disease and absence of Alzheimer's disease co-pathology - experienced greater clinical benefit with neflamapimod in Phase 2b clinical trial. PK/PD analyses of Phase 2b clinical data provide further insight into the drug plasma concentration levels of neflamapimod associated with a clinical effect. Findings further support neflamapimod's potential to target the underlying cause of disease in DLB and the company's patient enrichment strategy and dosing regimen for planned Phase 3 trial. The analyses presented at AD/PD reveal a consistently improving treatment effect in multiple clinical end points at progressively lower plasma pTau181 levels, which are associated with a higher percentage of DLB patients without AD co-pathology.